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Introduction
Worldwide, colorectal cancer (CRC) is a global challenge for the 
health care systems with more than 1.4 million primary cancers 
diagnosed every year; annually, approximately 695 000 patients 
die of the disease.1 Screening of the average risk populations 
may be one of the options to reduce the incidence and mortality 
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ABSTRACT: 
InTRoDuCTIon: Most of the subjects undergoing diagnostic colonoscopy do not have neoplastic bowel lesions. Potentially, some of the 
symptoms may therefore be caused by extracolonic malignancy, and subjects with persisting symptoms may need subsequent examina-
tions. Blood-based, cancer-associated biomarkers may aid in directing the examinations for other specific malignant diseases.
METhoDS: EDTA plasma samples available from a previous prospective study of subjects undergoing diagnostic colonoscopy were used 
for analysis of 18 protein biomarkers. The study population of 3732 subjects included 400 patients with colorectal cancer (CRC) and 177 
patients with extracolonic malignancies. Univariable analysis of the association of specific biomarkers and extracolonic cancers included 
those with 10 or more cases. Subsequently, reduced models of 4 or 6 biomarkers, respectively, were established by choosing those with the 
highest likelihood; age and sex were included as well.
RESulTS: Univariable analyses showed that CyFra21-1 had an area under curve (AUC) of 0.87 for lung cancers (n = 33), CA19-9 had an 
AUC of 0.85 for pancreatic cancer (n = 22), CA125 had an AUC of 0.95 for ovary cancer (n = 16), B2M had an AUC of 0.81 for non-Hodgkin 
lymphoma (n = 12), and total prostate-specific antigen had an AUC of 0.99 for prostate cancer (n = 10). The multivariable analysis of 4 or 6 
biomarkers plus age and sex as explanatory variables showed AUCs of 0.82 to 0.85 both for extracolonic cancers and CRC. The 4 biomark-
ers included in the model for detection of extracolonic cancers were CA125, hsCRP, CA19-9, and CyFra21-1; the 2 additional for the 6 bio-
markers model were CEA and Galectin-3. Similarly, the 4 biomarkers included in the model for detection of CRC were CEA, CyFra21-1, 
Ferritin, and HE4; the two additional for the 6 biomarkers model were hsCRP and Pepsinogen 2.
ConCluSIonS: Results of this study indicate that it may be possible to detect subjects that have an increased risk of extracolonic cancer 
following a colonoscopy without findings of neoplastic lesions. Combinations of various protein biomarkers may direct subsequent examina-
tion after colonoscopy with clean colorectum. The results, although preliminary, may form the basis for additional research directed both for 
primary examinations of subjects with symptoms of malignancy and subsequent examinations after colonoscopy.
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2 Biomarkers in Cancer 
of CRC,2,3 presumably due to detection of adenomas and CRC 
at early stages.2–4 At present, fecal immunochemical test (FIT) 
screening appears as the leading screening option with a sub-
stantial sensitivity and specificity5 and at a low cost benefit as 
well.6 Compliance issues may, however, reduce the clinical sen-
sitivity to less than 50% resulting in more than 50% of those 
subjects with nonsymptomatic neoplastic bowel lesions will 
not be identified by FIT screening.7 Therefore, present research 
has focus on developments of blood-based biomarkers that in 
various combinations may improve the current screening for 
CRC.8 Recent results have shown that a combination of 8 pro-
tein biomarkers associated with CRC may detect large bowel 
neoplasia.9 These results are retrieved from a cohort of subjects 
offered diagnostic colonoscopy and are currently validated in a 
major prospective screening-associated study.8
Previous results have indicated that increased protein bio-
marker levels in association with colonoscopy for large bowel 
neoplasia are, however, not only uniformly related to bowel 
lesions but may also be shown among subjects with clean colo-
rectum.10–12 Such facts may be a major challenge in validation 
and clinical implementation of blood-based biomarkers, as it 
may lead to both specificity and sensitivity issues that may 
reduce the acceptability in future screening for bowel neoplasia. 
Consequently, that may prompt research on identification, 
evaluation, and validation of biomarkers that may direct subse-
quent examination of subjects offered colonoscopy due to 
increased biomarker levels, but who are identified with clean 
colorectum.
A variety of blood-based biomarkers, including proteins is 
not uniformly associated with a specific malignant disease, 
but may be more or less associated with malignancy in gen-
eral.12 It was shown recently that subjects with increased bio-
marker levels and clean colorectum at diagnostic bowel 
endoscopy for CRC had an increased risk of having or devel-
oping extracolonic cancers within few years.13,14 The bio-
markers included in those reports were TIMP-1, CEA, 
CA19-9, and YLK-40. In the recent major study of protein 
biomarkers in subjects scheduled for diagnostic colonoscopy, 
177 patients with various extracolonic cancers were also diag-
nosed after clean colorectum, but with subsequent examina-
tion due to persisting symptoms.9 Indeed, some protein 
biomarkers are more associated with one malignancy than 
with others, such as prostate-specific antigen (PSA) to pros-
tate cancer, CA19-9 to pancreatic cancer, and HE4 to ovarian 
cancer.15–17 Additional analysis of some of these biomarkers 
in samples collected from that particular study9 could poten-
tially have been a help in directing subsequent examination 
for some of those extracolonic cancers.
Therefore, the primary aim of this study was to perform anal-
yses of 10 protein biomarkers in relation to specific malignancies 
and add those to the 8 protein biomarkers determined previ-
ously9 to identify single biomarkers or combinations that may be 
useful in directing examination subsequent to a colonoscopy 
with clean colorectum. The secondary aim was to improve an 
already established pilot biomarker profile for CRC.9
Materials and Methods
Study population
A total of 4698 subjects scheduled for first time ever colonos-
copy due to symptoms of colorectal neoplasia were prospec-
tively included from May 1, 2010, to November 30, 2012, at 7 
collaborating hospitals in Denmark.9 Biobanked samples from 
3732 subjects were available for this study; samples from 177 
patients with extracolonic malignancies diagnosed after the 
primary colonoscopy were available (Figure 1).
Demographic data including comorbidity were recorded 
before colonoscopy. Subjects unable to undergo complete 
colonoscopy and subjects with complete colonoscopy, but 
without bowel pathology and persisting symptoms, were 
offered additional examination, ie, gastroscopy, X-ray with 
barium enema, ultrasonography, computer-assisted tomog-
raphy, and/or magnetic resonance imaging. All malignan-
cies were histologically confirmed and stages classified 
according to relevant staging systems, such as TNM for 
solid tumors, Ann Arbor staging for Lymphoma, RAI stag-
ing for chronic lymphocytic leukemia, and International 
Staging System for Multiple Myeloma. Patients were fol-
lowed-up using the computerized, unique central personal 
registration number (cpr.nr.) given to all Danish citizens. 
Due to Danish legislation, all diagnoses of extracolonic 
malignancies were established and verified within 1 month 
after colonoscopy.
Sample collection, storage, handling, and processing
Blood samples were collected from an antecubital vein just 
before colonoscopy according to a validated standard operating 
procedure (SOP). The blood samples were collected by dedi-
cated research nurses, handled into serum, EDTA plasma, and 
buffy-coat samples, respectively, and finally stored at −80°C as 
previously described; the entire procedure was finalized within 
2 hours.9
When all samples were collected, EDTA plasma levels of 
protein biomarkers associated with CRC were determined on 
the entire cohort of 4698 subjects.9 Subsequently, the levels of 
β2-microglobulin (B2M), cancer antigen 125 (CA125), cancer 
antigen 15-3 (CA15-3), human epidermis antigen 4 (HE4), 
neuron-specific enolase (NSE), Pepsinogen 1 and 2, squamous 
cell cancer antigen (SCC), progastrin-related peptide 
(ProGRP), and total PSA (tPSA) were determined in EDTA 
plasma samples from the 3732 selected subjects using the 
Abbott ARCHITECT automated immunoassay and clinical 
chemistry platform. The rationale for inclusion of the specific 
biomarkers is shown in Table 1. Testing was performed at the 
Abbott Center of Excellence at Vrie University Medical Center 
(VUMC), Amsterdam, The Netherlands.
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Ethics
The Ethics Committee of The Capital Region of Denmark 
(H-3-2009-110) and The Danish Data Protection Agency 
(2008-41-2252) approved the study, which was performed 
according to the Helsinki II declaration. The REMARK 
(REporting recommendations for tumor MARKer prognostic 
studies) guidelines for running and reporting the study were 
followed whenever applicable.25
Statistics
All end points considered are binary and have been described 
in detail previously.9
Briefly, the 2 outcomes are CRC versus all others, but 
excluding extracolonic cancers, and extracolonic cancers versus 
all others, but excluding CRC. Univariable analyses were per-
formed for each of the 18 explanatory variables, and then mul-
tivariable analysis was performed including all explanatory 
Figure 1. Flowchart of the entire study.
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variables as well as age and sex. Both univariable and multivari-
able analyses were done using logistic regression models with 
the explanatory variables (not age and sex) log transformed. 
Analyses of specific cancers other than CRC were done for 
those malignancies with 10 or more cases except for unknown 
primary tumors as they were considered too heterogeneous. 
These analyses included the addition of biomarkers known to 
be associated with the specific cancer type. The results are pre-
sented by the receiver operating characteristic curves with area 
under curve (AUC) as a measure of discrimination. In addition, 
specificities at predefined sensitivities (70%, 80%, and 90%) are 
presented. In addition, a model reduction was done for each 
end point by selecting the best 4 or 6 biomarkers and age and 
sex in a backwards fashion identifying those with the highest 
likelihood score. The P values less than 5% were considered 
significant. SAS (v9.4, SAS Institute, Cary, NC, USA) and R 
(R Development Core Team, Vienna, Austria; http://www.R-
project.org) were used for analysis.
Results
Diagnoses and findings at colonoscopy or subsequent exami-
nations of the 3732 subjects were as follows: 400 with CRC, 
177 with extracolonic cancers, 502 with adenomas, 1021 with 
other benign bowel lesions, and 1632 with clean bowel. Stages 
for CRCs and extracolonic cancers are shown in Table 2. Most 
of the extracolonic cancers were diagnosed at late stages as 58% 
(104/177) had stage IV disease (Tables 2-5).
Univariable analyses of the single biomarkers to detect the 
specific extracolonic cancers of more than 10 cases showed that 
CyFra21-1 had an AUC of 0.87 for lung cancers (n = 33), 
CA19-9 had an AUC of 0.85 for pancreatic cancer (n = 22), 
CA125 had an AUC of 0.95 for ovary cancer (n = 16), B2M had 
an AUC of 0.81 for non-Hodgkin-lymphoma (n = 12), and 
tPSA had an AUC of 0.99 for prostate cancer (n = 10) (Table 6).
Application of univariable analysis of the 18 single bio-
markers on the entire group of patients with extracolonic can-
cers showed AUCs of 0.77 for CA125, CyFra21-1, and 
TIMP-1, respectively. Furthermore, HE4 had an AUC of 0.76, 
whereas AFP had the lowest ability to discriminate at an AUC 
of 0.52. Similar application of univariable analysis on the group 
of patients with CRC showed that CEA and CyFra21-1 had 
AUCs of 0.73, respectively. The only markers of the 10 addi-
tional single biomarkers that had discriminatory effects on 
CRC were B2M and HE4 with AUCs of 0.63, respectively.
Subsequently, specificities at fixed sensitivities for univaria-
ble analyses were assessed both for extracolonic cancers and 
CRC, respectively (Table 7). Among the included biomarkers, 
CyFra21-1 appeared as the best single protein for detection of 
Table 1. Overview of individual markers.
BIOMARKER DESCRIPTION REFERENCES
B2M B2M is often elevated in lymphoproliferative disease, ie, myeloma, B-cell lymphoma, and 
chronic lymphocytic leukemia. B2M levels may also be elevated in both connective tissue 
disorders and Crohn disease
Bataille et al18
CA125 CA125 is a glycoprotein produced at various places in the body; it is mostly associated with 
ovarian cancer but it has also been documented in relation to other cancers
Moore et al19
CA15-3 CA15-3 is a cell surface antigen that has been mostly examined in breast cancer but may 
also be elevated in several benign and malignant conditions
Colomer et al20
CyFra21-1 Several reports support that CyFra21-1 and other cytokeratin fragments are elevated in many 
cancers and most pronounced in the respiratory system
Li et al21
HE4 Is an acidic 4-disulfide core protein. It is a biomarker expressed by the epidermis and is used 
in ovarian cancer. It is also expressed in other cancers and may also be elevated in benign 
gynecological conditions and renal failure
Karlsen et al17
NSE Is a glycolytic enzyme arising from neurons. May be used in the detection of SCLC. Can also 
be elevated in other malignancies, ie, neuroendocrine disorders and uterine cancers. May 
also be elevated in benign lung and gastrointestinal disorders
Wang et al22
Pepsinogen 1 and 2 Is a proenzyme to pepsin produced by gastric chief cells. It can be interpreted as a ratio 
between Pepsinogen 1 and Pepsinogen 2. A ratio of less than 3 is indicative of gastric 
atrophy and possible malignancy in the stomach
Lomba-Viana et al23
ProGRP Is a neuropeptide hormone. It is important in differential diagnosis in small-cell lung cancer 
(SCLC) as it is secreted from these malignant cells
Yang et al24
SCC The biological function is a serine protease inhibitor in epidermal tissues. It is recommended 
in squamous cell carcinoma, ie, lung, anal, larynx, and head and neck. Has to be interpreted 
with caution in patients with nephrosis and dermatosis
Yang et al24
tPSA Total prostate-specific antigen (tPSA) is a glycoprotein in the prostate and other tissues. It is 
elevated in conditions of the prostate most notably prostate cancer. Serial measurements/
velocity may be advantageous
Carter et al15
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Table 2. Stages of malignant tumors.
SOLID TUMORS NO. OF CASES STAGE 1 STAGE 2 STAGE 3 STAGE 4 UNKNOWN STAGE AND HISTOLOGY
Colorectal cancer 400 82 127 109 84  
Lung cancer 33 1 6 25 1
Pancreatic cancer 22 4 17 1
Ovarian cancer 16 1 2 3 10  
Unknown primary 16 12 4
Prostate cancer 10 3 3 4  
Gastric cancer 9 1 3 1 4  
Hepatobiliary 8 2 2 4  
Renal cancer 7 2 2 3  
Anal cancer 6 2 2 1 1  
Breast cancer 4 1 1 2  
Small intestine cancer 3 3  
Mesothelioma 3 1 2  
Esophageal cancer 3 3  
Larynx 3 1 1 1  
Neuroendocrine 2 1 1  
Malignant melanoma 2 1 1  
Uterine cancer 1 1  
Testicular cancer 2 1 1  
Bladder cancer 1 1  
Adrenal cancer 1 1  
Table 3. Ann Arbor staging of B-cell lymphoma.
CANCER CASES STAGE 1 STAGE 2 STAGE 3 STAGE 4 X E A/B UNKNOWN
B-cell 
lymphoma
17 1 2 4 6 0 4
Table 4. International Staging System for Multiple Myeloma.
CANCER CASES STAGE 1 STAGE 2 STAGE 3
Multiple myeloma 5 2 1 2
Table 5. Chronic lymphocytic leukemia (CLL) (RAI stages).
CANCER CASES STAGE 0 STAGE 1 STAGE 2 STAGE 3 STAGE 4
CLL 3 0 1 1 1 0
both extracolonic cancers and CRC. To some extent, the chosen 
biomarkers appeared to be correlated; ie, Pepsinogen 1 and 
Pepsinogen 2 had a rank correlation of 0.69, and HE4, Pro-
GRP, B2M, TIMP-1, Galectin-3, TIMP-1, hs-CRP, and CyFra 
21-1 had rank correlations higher than 0.40 (data not shown), 
which suggests a need for specific considerations in interpreta-
tion of results of the full model. Therefore, the results of multi-
variable analyses are presented as a reduced model of 4 or 6 
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biomarkers, respectively. The single biomarker proteins with the 
highest detection rate was selected from that analysis.
The multivariable analysis of 4 or 6 biomarkers plus inclu-
sion of age and sex as explanatory variables showed AUCs of 
0.82 to 0.85 both for extracolonic cancers and CRC (Table 8). 
The 4 biomarkers included in the model for detection of extra-
colonic cancers were CA125, hsCRP, CA19-9, and CyFra21-1; 
the 2 additional for the 6 biomarkers model were CEA and 
Galectin-3. Similarly, the 4 biomarkers included in the model 
for detection of CRC were CEA, CyFra21-1, Ferritin, and 
HE4; the 2 additional for the 6 biomarkers model were hsCRP 
and Pepsinogen 2.
Multivariable analysis of the specificities at fixed sensitivi-
ties showed that the sensitivity for detection of the entire 
group of extracolonic cancers was 70% at 88% specificity, 80% 
at 72% specificity, and 90% at 44% specificity, respectively. 
Similarly, the sensitivity for detection of CRC was 70% at 82% 
specificity, 80% at 71% specificity, and 90% at 48% specificity, 
respectively.
Discussion
Frequently, subjects undergoing symptom-directed diagnostic 
colonoscopy appear to have clean colorectum. Among 3732 
subjects included in this study 1021 had clean colorectum, 
whereas 400 had CRC, 502 had adenomas, and 1632 had 
other benign bowel lesions. Due to persistent symptoms, 
some of the subjects with nonmalignant bowel lesions or 
clean colorectum needed subsequent additional examinations, 
Table 6. Univariate analysis of extracolonic cancers with 10 or more 
cases.
CANCER CASES BIOMARKERS AUC
Lung 33 CyFra21-1 0.87
Pancreatic 22 CA 19-9 0.85
Ovary 16 CA 125 0.95
Non-Hodgkin lymphoma 12 B2M 0.81
Prostate 10 tPSA 0.99
Table 7. Specificities at fixed sensitivities for univariate analysis of CRC and extracolonic cancers.
END POINT CRC EXTRACOLONIC CANCER
SENSITIVITY SENSITIVITY
70% 80% 90% 70% 80% 90%
MARKER SPECIFICITY SPECIFICITY SPECIFICITY SPECIFICITY SPECIFICITY SPECIFICITY
AFP 0.33 0.24 0.14 0.29 0.16 0.07
B2M 0.51 0.39 0.21 0.58 0.47 0.25
CA 125 0.32 0.22 0.12 0.46 0.29 0.17
CA15-3 0.32 0.22 0.12 0.46 0.29 0.17
Ca 19-9 0.43 0.30 0.15 0.46 0.33 0.12
CEA 0.61 0.46 0.28 0.49 0.36 0.17
CyFra21-1 0.61 0.47 0.30 0.69 0.56 0.29
Ferritin 0.37 0.24 0.13 0.41 0.21 0.08
Galectin 3 0.43 0.34 0.17 0.44 0.25 0.17
HE4 0.48 0.38 0.26 0.66 0.58 0.39
hsCRP 0.58 0.48 0.24 0.63 0.41 0.22
Pepsinogen 1 0.31 0.21 0.11 0.39 0.24 0.11
Pepsinogen 2 0.32 0.22 0.13 0.35 0.18 0.09
ProGRP 0.34 0.24 0.13 0.38 0.28 0.13
NSE 0.33 0.24 0.12 0.46 0.31 0.17
SCC 0.30 0.19 0.10 0.28 0.19 0.08
TIMP-1 0.51 0.43 0.25 0.70 0.56 0.40
tPSA 0.29 0.27 0.12 0.29 0.24 0.08
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and thereby extracolonic malignancies were identified in 177 
patients. This study focused on a selected part of the entire 
study cohort to address an important clinical question: Can 
blood-based biomarkers aid in directing subsequent examina-
tion for organ-specific malignancies after colonoscopy with find-
ing of a clean colorectum? The present preliminary results 
indicate that it may be possible, but this needs to be validated in 
future and sufficiently powered studies.
The results achieved by univariable analysis of the 18 single 
protein biomarkers, on the entire cohort of patients with 24 
different extracolonic malignancies (Tables 2-5), indicate that 
CA125, CyFra21-1, and TIMP-1 may have fair detection rates 
as the AUCs were 0.77, respectively; lower AUCs were shown 
for some of the other 18 biomarkers. Application of additional 
univariable analysis indicates that specific, single biomarkers 
may be useful in directing subsequent examination. Although 
the cohorts of various extracolonic malignant diseases had lim-
ited numbers, the AUCs ranged from 0.99 (tPSA for prostate 
cancer) via 0.95 (CA125 for ovary cancer) and 0.87 (CyFra21-1 
for lung cancer) and 0.85 (CA19-9 for pancreatic cancer) to 
0.81 (B2M for non-Hodgkin lymphoma). It must be taken 
into consideration, however, that most of the patients diag-
nosed with extracolonic malignancies had disseminated dis-
ease. This fact may have led to the very high AUCs for single 
biomarkers of the specific diseases. Subjects with clean colorec-
tum after diagnostic colonoscopy and with persisting symp-
toms may, however, benefit from a blood-based test that may 
aid in directing subsequent examination to identify the cause of 
the symptoms. Thereby, such subjects may avoid series of com-
plex and invasive examinations. In its present form, the tests 
may not be applicable in directing examination for primary, 
low-stage malignancies. Such tests may be based on the addi-
tion of other biomarker entities, including cell-free DNA anal-
yses,26,27 which recently have shown promising results. It is well 
known that cell-free DNA does not detect all malignancies 
with high sensitivity at high specificity, and therefore, combi-
nations of circulating protein and DNA biomarkers may be a 
future option to improve the clinical accuracy of the specific 
cancer tests.28
In multivariable analysis, panels of 4 or 6 biomarkers plus age 
and sex were identified. Regarding the primary end point, extra-
colonic cancers, the following markers were identified: CA125, 
hsCRP, Galectin-3, CEA, CA19-9, and CyFra21-1. With this 
panel, an AUC of 0.85 was achieved and thereby may aid as the 
diagnosis of patients with certain diseases. The specificities at 
fixed sensitivities ranged between 0.88 and 0.44 for this end 
point. In the secondary end point, an AUC of 0.84 was achieved 
and the following markers were identified: Pepsinogen 2, HE4, 
Hs-CRP, CEA, Ferritin, and CyFra21-1. The result was a slight 
improvement of the result shown in the previous study of pri-
mary CRC detection.9 For this end point, the specificities at 
fixed sensitivities ranged between 0.82 and 0.48.
Current research of early detection of large bowel neoplasia 
in screening procedures focuses on biomarkers that may have 
the highest possible specificity to reduce the numbers of false 
positives and thereby reduce subsequent colonoscopy. Such 
achievements may have influenced the sensitivity, however, 
which often is somewhat lower and may lead to subjects that are 
classified as false negative. This study has focused on the sensi-
tivity to direct examinations for extracolonic cancers subsequent 
to a colonoscopy, which had not led to identification of bowel 
neoplasia. As most of the examinations of subjects with symp-
toms of CRC are performed via the outpatient clinics, it is 
essential that examination procedures focus as much as possible 
on the risk of a malignant disease that may cause the symptoms. 
In particular, focused examinations may be urgent for subjects 
that have stage IV diseases as in this study. Due to the severity 
of disease, such patients need immediate initiation of the offered 
therapy. It is well known, however, that tests with high sensitivi-
ties often have lower specificities that may lead to more subjects, 
who are classified as false positives. Pros and cons on sensitivi-
ties and specificities are a subject of intense discussions, but the 
severity of the diseases must also be a part of the debate.
Although the results were achieved based on a limited num-
ber of patients, the study findings may lead to consideration of 
whether this testing approach could potentially be applicable 
in the primary evaluation of subjects with symptoms of various 
malignancies to direct primary examination. Thereby, some 
subjects may not need bowel preparation and subsequent colo-
noscopy, which may be associated with serious discomfort and 
side effects, particularly for fragile subjects. Testing with blood-
based biomarkers may have several advantages. First of all, 
blood collection for analysis of biomarkers appears to have high 
compliance rates.7,29 Second, testing with various blood-based 
protein biomarkers may lead to options of combinations, which 
appear to improve sensitivity and specificity as shown previ-
ously9 as well as in this study. Third, new biomarker entities 
such as genomics,30–34 epigenomics,35,36 cell-free DNA,26,27 
and metabolomics37 may lead to combinations of biomarker 
panels, which may yield improved sensitivity and specificity. 
Table 8. Multivariable analysis of various end points including 4 or 6 
best protein biomarkers plus age and sex as covariates.
END POINT IDENTIFIED MARKERS NO. OF 
COVARIATES
AUC
CRC Age, sex, Pepsinogen 2, 
HE4, hs-CRP, CEA, 
Ferritin, CyFra21-1
8 0.84
CRC Age, sex, HE4, CEA, 
Ferritin and CyFra21-1
6 0.82
Extracolonic 
cancer
Age, sex, CA125, hsCRP, 
Galectin-3, CEA, CA19-9, 
CyFra21-1
8 0.85
Extracolonic 
cancer
Age, sex, CA 125, hsCRP, 
CA19-9, CyFra21-1
6 0.84
Abbreviation: CRC, colorectal cancer.
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Fourth, due to noninvasive nature for analysis of blood-based 
biomarkers, testing can readily be repeated as needed; this may 
be an advantage in situations such as in monitoring treatment 
of subjects under surveillance due to risk of developing neo-
plastic diseases.13,14 Blood-based biomarker levels or presence 
may, however, be influenced by comorbidity and use of tobacco 
and/or alcohol. Application of combinations of various bio-
marker entities may reduce such influence and thereby improve 
interpretation of achieved results.
The strengths of this study include the total number of sub-
jects recruited, the fact that the extracolonic cancers were iden-
tified within the same examination process due to the symptoms 
that led to colonoscopy, that none were lost to follow-up, that 
the study recruited subjects in 7 institutions of 2 regions in 
Denmark (1 rural and 1 nonrural), that the samples were 
collected and handled according to a validated SOP, and finally 
that the study adhered to guidelines including REMARK 
whenever possible.25
The study has limitations, however, that must be taken 
into consideration in the interpretation. First of all, the 
numbers of specific extracolonic cancers were limited and 
therefore the statistical analysis was restricted to those with 
10 or more cases. Second, the number of subjects selected 
for the study was reduced to 3732 from the original 4698 
due to restrictions on samples availability; however, samples 
from all the 177 patients with extracolonic cancers were 
available. Third, the study was not initiated to identify bio-
markers for detection of extracolonic cancers, and therefore, 
the extracolonic findings were achieved by subsequent 
follow-ups for those who had no colonic findings but had 
persistent symptoms.
Conclusions
The results of this study indicate that it may be possible to 
detect subjects that have an increased risk of extracolonic 
cancer following a clean colonoscopy as previously hypothe-
sized.13 It appears that combinations of various protein bio-
markers may be useful to direct subsequent examination of 
patients with persistent symptoms, but who had clean colo-
rectum at colonoscopy. These results, although preliminary, 
may form the basis for additional research directed both for 
primary examinations of subjects with symptoms of malig-
nancy as indicated very recently by a multi-analyte blood 
test28 and subsequent examinations to a clean bowel at colo-
noscopy. From a clinical perspective, such future results will 
be of major importance in subjects with symptoms of malig-
nancy, as such testing may reduce the number of potential 
futile examinations.
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